Novel combinations comprising a phoshodiesterase-5 inhibitor and their use

A composition for treating a neurodegenerative disease in a subject comprising a phosphodiesterase 5 inhibitor in combination with at least one of the following medications:

• a selective serotonin reuptake inhibitor;
• a serotonin norepinephrine reuptake inhibitor;
• a cholinesterase inhibitor;
• a dopamine agonist;
• and
• a medication effective to increase the chemical concentrations of other neurotransmitters, selected from amino acids, monoamines, neuropeptides, other agents capable of primary neurotransmission in the synaptic clefts, and combinations thereof.

Use of a phosphodiesterase 5 inhibitor (PI5) in the manufacture of a medicament for treating a neurodegenerative disease in a subject, wherein the medicament is a composition that further comprises at least one of the following medications:

• a selective serotonin reuptake inhibitor;
• a serotonin norepinephrine reuptake inhibitor;
• a cholinesterase inhibitor
• a dopamine agonist;
• and
• a medication effective to increase the chemical concentrations of other neurotransmitters, selected from amino acids, monoamines, neuropeptides, other agents capable of primary neurotransmission in the synaptic clefts, and combinations thereof.